(Source: Affimed NV) 7fbc2669-d166-4590-8138-1a241acda2ea.pdf FOR IMMEDIATE RELEASE Affimed Presents Data on Potency of NK- and T-cell EGFRvIII TandAbs at SITC -- NK- and T-cell TandAbs Demonstrate Similar Robust Potency -- Heidelberg, Germany, November 6, 2015 - Affimed N.V. (Nasdaq: AFMD), a clinical- stage biopharmaceutical company developing highly targeted cancer immunotherapies, yesterday presented first data on the Company's proprietary NK- and T-cell TandAbs generated against the tumor-specific variant III of the Epidermal Growth Factor Receptor (EGFRvIII), at the annual Society for Immunotherapy of Cancer (SITC) conference in National Harbor, Maryland. Results showed that the...
↧